Kythera Biopharmaceuticals Inc has initiated a second Phase II clinical trial to evaluate its proprietary product, ATX-101, for the reduction of unwanted submental (under chin) fat. This clinical trial is the second in a series of Phase II studies of ATX-101 in aesthetic applications and is aimed at assessing the safety and effectiveness of ATX-101 as a “liposculpting” agent. The multi-center, randomized, double-blind, placebo-controlled, Phase II trial will enroll approximately 60 patients in the UK, Canada and Australia to assess safety, tolerability and efficacy across two dosing paradigms of ATX-101 in reducing small volumes of submental fat.